Abstract
The SARS-CoV-2 Omicron BA.1 variant has been supplanted in many countries by the BA.2 sub-lineage. BA.2 differs from BA.1 by about 21 mutations in its spike. Human anti-spike monoclonal antibodies (mAbs) are used for prevention or treatment of COVID-19. However, the capacity of therapeutic mAbs to neutralize BA.1 and BA.2 remains poorly characterized. Here, we first compared the sensitivity of BA.1 and BA.2 to neutralization by 9 therapeutic mAbs. In contrast to BA.1, BA.2 was sensitive to Cilgavimab, partly inhibited by Imdevimab and resistant to Adintrevimab and Sotrovimab. Two combinations of mAbs, Ronapreve (Casirivimab + Imdevimab) and Evusheld (Cilgavimab + Tixagevimab), are indicated as a pre-exposure prophylaxis in immunocompromised persons at risk of severe disease. We analyzed sera from 29 such individuals, up to one month after administration of Ronapreve and/or Evusheld. After treatment, all individuals displayed elevated antibody levels in their sera and neutralized Delta with high titers. Ronapreve recipients did not neutralize BA.1 and weakly impaired BA.2. With Evusheld, neutralization of BA.1 and BA.2 was detected in 19 and 29 out of 29 patients, respectively. As compared to Delta, titers were more severely decreased against BA.1 (344-fold) than BA.2 (9-fold). We further report 4 breakthrough Omicron infections among the 29 participants. Therefore, BA.1 and BA.2 exhibit noticeable differences in their sensitivity to therapeutic mAbs. Anti-Omicron activity of Ronapreve, and to a lesser extent that of Evusheld, is reduced in patients’ sera, a phenomenon associated with decreased clinical efficacy.
Competing Interest Statement
T.B, C.P., H.M. and O.S. have a pending patent application for an anti-RBD mAb not used in this study (PCT/FR2021/070522).
Funding Statement
Work in OS lab is funded by Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur, Fondation pour la Recherche Medicale (FRM), ANRS, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR/FRM Flash Covid PROTEO-SARS-CoV-2, ANR Coronamito, and IDISCOVR. Work in UPBI is funded by grant ANR-10-INSB-04-01 and Region Ile-de-France program DIM1-Health. DP is supported by the Vaccine Research Institute. GB acknowledges support from the Internal Funds KU Leuven under grant agreement C14/18/094, and the Research Foundation - Flanders (Fonds voor Wetenschappelijk Onderzoek - Vlaanderen, G0E1420N, G098321N). PM acknowledges support from a COVID19 research grant of Fonds Wetenschappelijk Onderzoek/Research Foundation Flanders (grant G0H4420N). PM acknowledges support of a COVID19 research grant of Fonds Wetenschappelijk Onderzoek/Research Foundation Flanders (grant G0H4420N) and Internal Funds KU Leuven (grant 3M170314). ESL acknowledges funding from the INCEPTION program (Investissements d Avenir grant ANR-16-CONV-0005). The funders of this study had no role in study design, data collection, analysis and interpretation, or writing of the article.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study is based on two cohorts, which were both approved by their respective ethical committees. Details are provided below and in the methods of the manuscript, in the section cohorts (page 9).
The Orleans cohort is an ongoing prospective, monocentric, longitudinal, observational cohort clinical study aiming to describe the kinetic of neutralizing antibodies after SARS-CoV-2 infection or vaccination (ClinicalTrials.gov Identifier: NCT04750720). This study was approved by the Est II (Besancon) ethical committee.
The Cochin cohort is a prospective, monocentric, longitudinal, observational clinical study (NCT04870411) enrolling immunocompromised individuals with rheumatic diseases, aiming at describing immunological responses to COVID-19 vaccine in patients with autoimmune and inflammatory diseases treated with immunosuppressants and/or biologics. Ethics approval was obtained by Comite de Protection des Personnes Nord-Ouest II.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data supporting the findings of this study are available within the article or from the corresponding authors upon request.
